指南与共识临床免疫分子诊断质量管理与危急值

胃食管腺癌HER2检测与临床决策指南

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
指南 / 共识 · Am J Clin Pathol · 2016-11-14

美国病理学家协会、美国临床病理学会和美国临床肿瘤学会召集专家小组,系统综述文献,制定胃食管腺癌(GEA)HER2检测循证指南,提出11条推荐,涵盖所有晚期GEA候选靶向治疗患者应在治疗前评估HER2状态、HER2阳性者初始治疗推荐联合化疗和HER2靶向药物,并为病理医生提供组织选择、检测算法、评分、报告和质量保证指导。

要点

  • 所有晚期GEA且适合HER2靶向治疗的患者,应在开始靶向治疗前评估HER2状态。
  • HER2阳性晚期GEA患者初始治疗推荐联合化疗和HER2靶向药物。
  • 病理医生需按指南进行组织形态选择、检测算法、评分、报告和实验室质量保证。

核心结论

  • 该指南为晚期GEA患者HER2检测提供具体推荐,并解决相关技术问题和结果的临床意义。

研究设计与样本

  • 美国病理学家协会、美国临床病理学会和美国临床肿瘤学会召集专家小组,系统综述文献,制定循证指南。

主要发现

  • 专家小组提出11条推荐,获得开放评论参与者强烈同意。

关键数值与推荐

  • 推荐所有晚期GEA且适合HER2靶向治疗的患者在开始靶向治疗前评估HER2状态。
  • 推荐HER2阳性晚期GEA患者初始治疗为联合化疗加HER2靶向药物。
  • 为病理医生提供肿瘤组织形态选择、检测算法、评分方法、结果解释和报告、实验室质量保证的指导。

临床怎么用

  • 临床医生应在HER2靶向治疗前对晚期GEA患者进行HER2检测,HER2阳性者初始治疗选择联合化疗和HER2靶向药物。
  • 病理医生应遵循指南进行组织选择、检测、评分和报告,并实施实验室质量保证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. OBJECTIVES: To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. DESIGN: The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. RESULTS: The panel is proposing 11 recommendations with strong agreement from the open-comment participants. RECOMMENDATIONS: The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. CONCLUSIONS: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol. 2016. PMID: 28077399. doi:10.1093/ajcp/aqw206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。